Introduction
Glaucoma is a multifactorial neurodegenerative disease affecting 64.3 million people worldwide (Tham et al., 2014). Despite vigorous research on new treatments, those that reduce intraocular pressure (IOP) remain the gold standard. However, their effectiveness has been questioned as they only slow down degeneration without significantly reversing or stopping the disease (Osborne et al., 2016b). Recent studies have, therefore, investigated the causative roles of other processes, including glutamate toxicity, glial overactivation, etc., (Mann et al., 2005; Chong and Martin, 2015; Lopez Sanchez et al., 2016; Vecino et al., 2016).
Mitochondrial dysfunction is another widely studied causal process in the development of glaucoma and has also been investigated as a potential drug target. For example, red light therapy, manipulation of the mammalian target of rapamycin (mTOR) pathway, and nicotinamide treatment are three recently investigated clinical therapies for glaucoma-related mitochondrial dysfunction (Osborne et al., 2016a,b; Williams et al., 2017). Mitochondrial activity is intimately linked to oxidative metabolism and reactive oxygen species (ROS) formation (Schieke et al., 2006). ROS production is known to cause retinal ganglion cell (RGC) apoptosis and subsequent vision loss. Furthermore, while mitochondrial function is regulated by multiple pathways, calcium signaling likely plays a key role (Vosler et al., 2008; Hurst et al., 2017). In fact, plasma membrane calcium channel inhibitors were recently found to arrest acute axonal degeneration and improve regeneration after optic nerve crush (Ribas et al., 2017). A different combination of calcium permeability inhibitors also preserved optokinetic reflex following partial optic nerve transection (Savigni et al., 2013). While the inhibitors utilized in these studies targeted calcium channels in the plasma membrane, their effects indicate that ROS generation and calcium signaling, which are significantly regulated by the mitochondria, are critical during glaucoma pathogenesis.
Recently, a mitochondrial-specific drug delivery system was shown to be effective in increasing drug concentration in mitochondria in hepatic injuries and drug-resistant cancer cells (Yamada and Harashima, 2017; Yamada et al., 2017). However, the full potential of this system (and other similar systems) has not been fully evaluated with regards to calcium regulation in the diseased retina. In this opinion article, we provide a brief discussion concerning the role of mitochondrial calcium regulation during glaucoma pathogenesis as well as insight concerning the potential use of mitochondrial-specific drug delivery during disease treatment. We believe that the extensive research and overlap in the fields of glaucoma and mitochondrial disease/aging (including calcium signaling dysfunction) ultimately lead to the therapeutic utilization of mitochondrial-specific delivery of calcium channel regulators during glaucoma and other retinal/neurodegenerative diseases (Figure 1).
Figure 1
Glaucoma pathophysiology
Glaucoma is a two phase degenerative disease. The first phase involves a primary insult to the RGCs (Levkovitch-Verbin et al., 2003). Confirmed risk factors/insults for glaucoma include high IOP, ischemia, and aging. While these direct insults have classically been investigated as the cause of glaucoma-related vision loss, recent evidence indicates that damage to the visual cortex and/or optic nerve (i.e., distal axonopathy), which is then propagated to the retina following stress on axonal transport systems, may play a significant role in the initiation of the disease (Calkins and Horner, 2012; Crish and Calkins, 2015). Ultimately, all of these insults disrupt oxygen supply and alter retinal function. Furthermore, mitochondrial oxidative phosphorylation is significantly less effective in the affected RGCs, and energy production depends more on glycolysis and the tricarboxylic acid cycle. This change in energy supply causes oxidative stress and reduced ROS consumption, leading to mitochondrial damage and further ROS accumulation (Nguyen et al., 2011). While it has been hypothesized that RGCs can still function normally in this reduced energy state (Osborne et al., 2016b), they are more susceptible to secondary insults.
Secondary affronts to the RGCs can come in various forms. For example, primary insult-induced activation of retinal microglia and astrocytes as well as altered Müller cell function have detrimental secondary consequences related to the release of pro-inflammatory markers as well as other cytotoxic substances, including glutamate, nitrogen oxide, etc., in the extracellular space surrounding the RGCs. Furthermore, aged/dysfunctional mitochondria within the RGCs can also act as secondary stressors. In aged mitochondria, the initial increase in oxidative stress and reduced ROS consumption is amplified, resulting in a vicious positive feedback loop involving ROS along with damage to mitochondrial and nuclear DNA (Nguyen et al., 2011). This damage is largely irreversible as the repair mechanisms are often impaired in aged mitochondria. ATP production in cells with damaged mitochondria also becomes increasingly more difficult, ultimately leading to calcium dysregulation. As calcium is a known trigger for glutamate release (Neher and Sakaba, 2008), disrupted calcium signaling in aged mitochondria can further exacerbate primary insult-induced glutamate toxicity. Interestingly, increased glutamate concentration also mediates calcium influx (Wojda et al., 2008), indicating multiple points of crosstalk between mitochondrial calcium signaling and neuronal function.
Mitochondrial calcium as a key player in glaucoma
Mitochondria have two membrane layers. At the outer membrane, calcium influx is largely mediated through voltage-dependent anion channels (VDACs) (Cali et al., 2012; Rizzuto et al., 2012). Some reports suggest that open-state VDACs facilitate metabolite flow and prevent cytochrome C release, while closed-state VDACs mediate the opposite (Tan and Colombini, 2007; Hoppe, 2010; Williams et al., 2013). Further, elevated intracellular calcium concentrations appear to increase VDAC1 oligomerization and downstream apoptosis (Keinan et al., 2013). This increase in oligomerization has been demonstrated to be mediated specifically by mitochondrial, rather than cytosolic, calcium, providing a direct link between mitochondrial calcium and apoptosis.
At the inner membrane, calcium influx from the intermembrane space into the matrix is largely regulated by calcium-activated mitochondrial calcium uniporters (MCUs) (Cali et al., 2012). Although MCU calcium affinity is low, their effect on calcium concentration is significant as they mediate calcium inflow in response to the negative membrane potential/calcium gradient created by pumping protons across the membrane during oxidative phosphorylation. Thus, MCUs are functionally dependent on both intracellular calcium concentration and energy demand (Tsai et al., 2017). The links between calcium and energy are further strengthened by the calcium-dependent activation of three metabolic enzymes, pyruvate, α-ketoglutarate, and isocitrate dehydrogenases, all of which function in the tricarboxylic acid cycle (Cali et al., 2012). MCU function also depends on the proximity of the mitochondria to other calcium regulating organelles, including the endoplasmic reticulum, sarcoplasmic reticulum, and plasma membrane, which can alter the local calcium concentration (Kirichok et al., 2004; Rizzuto et al., 2012).
Cellular calcium homeostasis, whereby nanomolar levels of free calcium are found in the cytosol, is maintained, at least in part, via effective buffering mechanisms, including pH and phosphate/adenosine availability. Additional intermitochondrial buffering mechanisms involve calcium efflux via electrogenic Ca2+/3Na+ exchangers (mNCXs) and/or electroneutral Ca2+/2H+ exchangers (mHCXs) located on the inner mitochondrial membrane. mNCXs are the main efflux channels in excitable tissues, including RGCs, while mHCXs are found mainly in non-excitable tissues (Hoppe, 2010). Interestingly, these efflux systems appear to change into influx pathways during glaucoma (Wojda et al., 2008). In aged neurons, the expression of calcium buffering proteins, including calbindin-D28k, calretinin, and parvalbumin, is also reduced (Bu et al., 2003). Together, these changes in efflux levels and calcium buffering protein expression significantly alter calcium gradients, cytosolic calcium levels (Williams et al., 2013), and mitochondrial membrane polarization (Wojda et al., 2008), resulting in altered/inefficient oxidative phosphorylation, ROS accumulation, downstream changes in mitochondrial function, and neuronal cell survival.
In retinal neurons, intracellular free calcium overload triggers calpain activation which can subsequently initiate apoptotic cascades (Sharma and Rohrer, 2004; Huang et al., 2010; Kar et al., 2010). Calpain is a calcium-dependent cysteine protease that, once activated, cleaves pro-apoptotic B-cell lymphoma (Bcl)-2 family members as well as apoptosis-inducing factor (AIF) and inner membrane mNCXs (Vosler et al., 2008). Calpain activation is also related to the formation and opening of mitochondrial permeability transition pores (mPTPs) (Cali et al., 2012; Bernardi and Di Lisa, 2015). mPTPs are multi-protein complexes that facilitate calcium efflux. However, unlike mNCXs, once the mPTPs are opened, the inner membrane is irreversibly permeabilized, resulting in uncontrolled dissipation of the electrochemical gradient, ATP depletion, ROS production, cytochrome C efflux, and mitochondrial swelling (Rasheed et al., 2017). Notably, increased cytoplasmic cytochrome C levels not only facilitate additional calpain activation, but the coupling of cytochrome C with apoptosis protease-activating factor (APAF)-1 results in apoptosome formation. Apoptosomes recruit and activate caspase-9 and downstream caspase-mediated apoptosis. Interestingly, activation of various caspases also feeds back into the process to further activate pro-apoptotic Bcl-2 proteins family members and increase mitochondrial permeability.
Calcium-related drug treatments in the ocular environment
Various calcium regulating therapies have been investigated for their use in treating visual neurodegeneration (Kamel et al., 2017). Indeed, in the dorsal lateral geniculate nucleus and superior colliculus as well as RGCs, lomerizine, a well-known plasma membrane calcium channel blocker, has been used to manage neuronal degeneration (Ito et al., 2010; Selt et al., 2010). Various combinations of calcium channel inhibitors, including the L-/N-type channel blocker amlodipine, T-type channel blocker amiloride, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor blockers, and purinergic receptor blockers, also increase RGC survival, reduce axonal degeneration, and increase axonal regeneration in both partial optic nerve transection (Savigni et al., 2013) and crush models (Ribas et al., 2017). However, the effects on visual function preservation were not significant.
In glaucoma and retinitis pigmentosa models, inhibition of calpain signaling has also been demonstrated to be beneficial for RGC and photoreceptor survival, respectively. This is not surprising as the detrimental effects of calcium overload are mediated largely through calpain activation. Latanoprost, an ocular anti-hypertension drug, for example, modulates its neuroprotective effects in this calpain-mediated manner (Yamamoto et al., 2017).
Unfortunately, beyond these studies using agents against calcium signaling in the plasma membrane, other mitochondria-specific calcium channel regulators to block detrimental calcium changes have not been intensively studied and none have been investigated as a glaucoma treatment option. Notably, calcium can be transported across the outer and inner mitochondrial membranes via VDACs and MCUs, respectively, as well as during unregulated diffusion through mPTPs, making each of these protein complexes a potential target for calcium regulation during disease. While a number of agents have been used to block mPTPs (Kajitani et al., 2007; Halestrap and Richardson, 2015), treatment with these agents leaves the causative upstream changes in calcium concentration and channel function largely unchecked. Thus, targeting VDACs and/or MCUs and avoiding mPTP formation altogether would potentially be more advantageous. For example, an anti-VDAC antibody has been shown to reduce cytochrome C release from mitochondria (Madesh and Hajnóczky, 2001). Unfortunately, directly altering VDAC function in this manner can also manipulate the transport of other essential metabolites (Camara et al., 2017). In cancer, blocking VDACs results in apoptosis (Shoshan-Barmatz et al., 2017), which is counterproductive to the cellular rescue required during glaucoma treatment. Alternatively, an MCU blocker, Ru360, was demonstrated to alter ion transport through these channels as well as block iron overload and has the advantage of having minimal effects on other cellular functions (Sripetchwandee et al., 2013). This same blocker was also previously shown to prevent the accumulation of mitochondrial free calcium despite high cytosolic free calcium concentrations in post-ischaemic rat heart cells (de Jesús García-Rivas et al., 2005). Lastly, this drug also maintains normal oxidative phosphorylation levels and prevents mPTP opening, while other organelles and cellular processes are unaffected, making it a drug of interest for glaucoma therapy.
Mitochondrial-specific drug delivery as a means to treat glaucoma
Organelle-specific drug targeting itself is not novel, being reviewed in multiple excellent publications (Sakhrani and Padh, 2013; Zhang and Zhang, 2016). While mitochondrial-specific drug targeting has not been applied to glaucoma, researchers have been actively proposing new mitochondrial delivery/transporter systems to target this organelle in other diseases. For example, a liposomal-based carrier was recently described that uses octaarginine modification, electrostatic attraction, and membrane fusion to promote mitochondrial uptake (Yamada and Harashima, 2017). This style of “MITO-porter” was then used to deliver coenzyme Q10 in mice with hepatic ischemic/reperfusion injuries and mediated a significant decrease in serum alanine aminotransferase (ALT) (Yamada et al., 2015). Another study utilized a MITO-porter system to target doxorubicin to the mitochondria of drug-resistant cancer cells, successfully destroying these cells (Yamada et al., 2017). Other nanotechnology techniques have also been employed, including a recent hybrid of polylactide-co-glycolide nanoparticles and mitochondria-penetrating particles (Selmin et al., 2017; Figure 1, bottom panel). Taken together, the evidence emerging from these investigations provides a solid foundation for the continued study of these delivery systems in other cellular contexts.
Delivery of agents used to modulate channel function along with the expression of other essential compounds (e.g., cytochrome C, ATP, etc.,) in concentrated amounts directly to the mitochondria during glaucoma using these systems would allow some of the downstream detrimental changes to be managed before vision loss. While some current (e.g., Ru360) and future drugs targeting mitochondrial calcium channels already innately target the mitochondria, the use of MITO-porters and similar delivery systems would not only allow higher concentrations to be delivered, but would also avoid any unknown effects on other organelles. Furthermore, delivery systems could also be used to package multiple drugs/compounds together in order to have the greatest therapeutic effect. Ultimately, these drugs would collectively reduce calcium efflux and restore calcium homeostasis as well as prevent mPTP formation, ATP depletion, ROS production, and cytochrome C dissipation. Doing so would prevent the second wave of apoptosis, allowing the cells to function normally even after the initial insult. While these drug delivery systems are not currently used as an ocular disease treatment, their potential to transport drugs to the retina and/or optic nerve/visual cortex that will subsequently manipulate mitochondrial function is a promising research avenue for novel treatment development for glaucoma as well as other retinal pathologies.
Conclusions
Mitochondrial dysfunction and the associated changes in calcium homeostasis, ROS production, and energy supply are intimately related to RGC death/dysfunction during glaucoma, making it an attractive treatment target. Mitochondrial-targeting drug delivery systems, which have been developed and validated in other cellular environments, could potentially avoid these issues by packaging multiple drugs and delivering them at high concentrations directly to the mitochondria. In discussing the recent advances in these techniques within the context of mitochondrial calcium regulation during glaucoma for the first time, we pose the question: Is this the future of glaucoma treatment? The relationships highlighted in multiple keystone studies investigating glaucoma and mitochondrial disease/aging in addition to the essential role of calcium signaling in these processes indicate an affirmative answer. Thus, while the full potential of these systems has yet to be fully established, we believe that mitochondrial-specific delivery of calcium channel regulators could effectively change how glaucoma and other neurodegenerative diseases affecting the retina are treated.
Statements
Author contributions
All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.
Funding
This work was supported by a grant from Seed Funding for Basic Science Research at the University of Hong Kong.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AbelsonM. B.GilbertC. M.SmithL. M. (1988). Sustained reduction of intraocular pressure in humans with the calcium channel blocker verapamil. Am. J. Ophthalmol.105, 155–159. 10.1016/0002-9394(88)90179-1
2
Abu-AmeroK. K.MoralesJ.BosleyT. M. (2006). Mitochondrial abnormalities in patients with primary open-angle glaucoma. Invest. Ophthalmol. Vis. Sci.47, 2533–2541. 10.1167/iovs.05-1639
3
AlmasiehM.LevinL. A. (2017). Neuroprotection in glaucoma: animal models and clinical trials. Annu. Rev. Vis. Sci. 3, 91–120. 10.1146/annurev-vision-102016-061422
4
AlmasiehM.WilsonA. M.MorquetteB.Cueva VargasJ. L.Di PoloA. (2012). The molecular basis of retinal ganglion cell death in glaucoma. Prog. Retin. Eye Res.31, 152–181. 10.1016/j.preteyeres.2011.11.002
5
AraieM.MayamaC. (2011). Use of calcium channel blockers for glaucoma. Prog. Retin. Eye Res.30, 54–71. 10.1016/j.preteyeres.2010.09.002
6
AugustineG. J.CharltonM. P.SmithS. J. (1987). Calcium action in synaptic transmitter release. Annu. Rev. Neurosci.10, 633–693. 10.1146/annurev.ne.10.030187.003221
7
BabcockD. F.HerringtonJ.GoodwinP. C.ParkY. B.HilleB. (1997). Mitochondrial participation in the intracellular Ca2+ network. J. Cell Biol.136, 833–844. 10.1083/jcb.136.4.833
8
BallardJ. W.WhitlockM. C. (2004). The incomplete natural history of mitochondria. Mol. Ecol.13, 729–744. 10.1046/j.1365-294X.2003.02063.x
9
BarotM.GokulgandhiM. R.MitraA. K. (2011). Mitochondrial dysfunction in retinal diseases. Curr. Eye Res.36, 1069–1077. 10.3109/02713683.2011.607536
10
BattigelliA.RussierJ.VenturelliE.FabbroC.PetronilliV.BernardiP.et al. (2013). Peptide-based carbon nanotubes for mitochondrial targeting. Nanoscale5, 9110–9117. 10.1039/c3nr02694a
11
BeattyJ. F.KrupinT.NicholsP. F.BeckerB. (1984). Elevation of intraocular pressure by calcium channel blockers. Arch. Ophthalmol.102, 1072–1076. 10.1001/archopht.1984.01040030866035
12
BernardiP.Di LisaF. (2015). The mitochondrial permeability transition pore: molecular nature and role as a target in cardioprotection. J. Mol. Cell. Cardiol.78, 100–106. 10.1016/j.yjmcc.2014.09.023
13
BerridgeM. J. (1997). Elementary and global aspects of calcium signalling. J. Physiol.499(Pt 2), 291–306. 10.1113/jphysiol.1997.sp021927
14
BreuerM. E.KoopmanW. J.KoeneS.NooteboomM.RodenburgR. J.WillemsP. H.et al. (2013). The role of mitochondrial OXPHOS dysfunction in the development of neurologic diseases. Neurobiol. Dis.51, 27–34. 10.1016/j.nbd.2012.03.007
15
BriniM.CarafoliE. (2000). Calcium signalling: a historical account, recent developments and future perspectives. Cell. Mol. Life Sci.57, 354–370. 10.1007/PL00000698
16
BrookesP. S.YoonY.RobothamJ. L.AndersM. W.SheuS. S. (2004). Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am. J. Physiol. Cell Physiol.287, C817–C833. 10.1152/ajpcell.00139.2004
17
BuJ.SathyendraV.NagykeryN.GeulaC. (2003). Age-related changes in calbindin-D28k, calretinin, and parvalbumin-immunoreactive neurons in the human cerebral cortex. Exp. Neurol.182, 220–231. 10.1016/S0014-4886(03)00094-3
18
CalabreseV.ScapagniniG.Giuffrida StellaA. M.BatesT. E.ClarkJ. B. (2001). Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity. Neurochem. Res.26, 739–764. 10.1023/A:1010955807739
19
CaliT.OttoliniD.BriniM. (2012). Mitochondrial Ca2+ as a key regulator of mitochondrial activities. Adv. Exp. Med. Biol.942, 53–73. 10.1007/978-94-007-2869-1_3
20
CalkinsD. J. (2012). Critical pathogenic events underlying progression of neurodegeneration in glaucoma. Prog. Retin. Eye Res.31, 702–719. 10.1016/j.preteyeres.2012.07.001
21
CalkinsD. J.HornerP. J. (2012). The cell and molecular biology of glaucoma: axonopathy and the brain. Invest. Ophthalmol. Vis. Sci.53, 2482–2484. 10.1167/iovs.12-9483i
22
CamaraA. K. S.ZhouY.WenP. C.TajkhorshidE.KwokW. M. (2017). Mitochondrial VDAC1: a key gatekeeper as potential therapeutic target. Front. Physiol.8:460. 10.3389/fphys.2017.00460
23
CarafoliE. (1986). Membrane transport in the cellular homeostasis of calcium. J. Cardiovasc. Pharmacol.8 (Suppl. 8), S3–S6. 10.1097/00005344-198600088-00002
24
CarafoliE.KleeC. (1999). Calcium as a Cellular Regulator. New York, NY: Oxford University Press.
25
CarafoliE.TiozzoR.LugliG.CrovettiF.KratzingC. (1974). The release of calcium from heart mitochondria by sodium. J. Mol. Cell. Cardiol.6, 361–371. 10.1016/0022-2828(74)90077-7
26
CarelliV.Ross-CisnerosF. N.SadunA. A. (2004). Mitochondrial dysfunction as a cause of optic neuropathies. Prog. Retin. Eye Res.23, 53–89. 10.1016/j.preteyeres.2003.10.003
27
CassonR. J.ChidlowG.WoodJ. P.CrowstonJ. G.GoldbergI. (2012). Definition of glaucoma: clinical and experimental concepts. Clin. Exp. Ophthalmol.40, 341–349. 10.1111/j.1442-9071.2012.02773.x
28
ChanM. S.LiuL. S.LeungH. M.LoP. K. (2017). Cancer-cell-specific mitochondria-targeted drug delivery by dual-ligand-functionalized nanodiamonds circumvent drug resistance. ACS Appl. Mater. Interfaces9, 11780–11789. 10.1021/acsami.6b15954
29
ChanceB. (1965). The energy-linked reaction of calcium with mitochondria. J. Biol. Chem.240, 2729–2748.
30
ChangE. E.GoldbergJ. L. (2012). Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement. Ophthalmology119, 979–986. 10.1016/j.ophtha.2011.11.003
31
ChhetriJ.GuevenN. (2016). Targeting mitochondrial function to protect against vision loss. Expert Opin. Ther. Targets20, 721–736. 10.1517/14728222.2015.1134489
32
ChinneryP. F. (2015). Mitochondrial disease in adults: what's old and what's new?EMBO Mol. Med.7, 1503–1512. 10.15252/emmm.201505079
33
ChongR. S.MartinK. R. (2015). Glial cell interactions and glaucoma. Curr. Opin. Ophthalmol.26, 73–77. 10.1097/ICU.0000000000000125
34
ChouchaniE. T.PellV. R.GaudeE.AksentijevićD.SundierS. Y.RobbE. L.et al. (2014). Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature515, 431–435. 10.1038/nature13909
35
ChrysostomouV.RezaniaF.TrounceI. A.CrowstonJ. G. (2013). Oxidative stress and mitochondrial dysfunction in glaucoma. Curr. Opin. Pharmacol.13, 12–15. 10.1016/j.coph.2012.09.008
36
ClaphamD. E. (1995). Calcium signaling. Cell80, 259–268. 10.1016/0092-8674(95)90408-5
37
ConsoliD.RamloganR. (2008). Out of sight: problem sequences and epistemic boundaries of medical know-how on glaucoma. J. Evol. Econ.18, 31–56. 10.1007/s00191-007-0074-4
38
CortesL. A.CastroL.PesceB.MayaJ. D.FerreiraJ.Castro-CastilloV.et al. (2015). Novel gallate triphenylphosphonium derivatives with potent antichagasic activity. PLoS ONE10:e0136852. 10.1371/journal.pone.0136852
39
CrishS. D.CalkinsD. J. (2011). Neurodegeneration in glaucoma: progression and calcium-dependent intracellular mechanisms. Neuroscience176, 1–11. 10.1016/j.neuroscience.2010.12.036
40
CrishS. D.CalkinsD. J. (2015). Central visual pathways in glaucoma: evidence for distal mechanisms of neuronal self-repair. J. Neuroophthalmol.35(Suppl. 1), S29–S37. 10.1097/WNO.0000000000000291
41
CuiH.LiF.ChenD.WangG.TruongC. K.EnnsG. M.et al. (2013). Comprehensive next-generation sequence analyses of the entire mitochondrial genome reveal new insights into the molecular diagnosis of mitochondrial DNA disorders. Genet. Med.15, 388–394. 10.1038/gim.2012.144
42
de Jesús García-RivasG.Guerrero-HernándezA.Guerrero-SernaG.Rodríguez-ZavalaJ. S.ZazuetaC. (2005). Inhibition of the mitochondrial calcium uniporter by the oxo-bridged dinuclear ruthenium amine complex (Ru360) prevents from irreversible injury in post-ischemic rat heart. FEBS J.272, 3477–3488. 10.1111/j.1742-4658.2005.04771.x
43
Del CastilloJ.KatzB. (1956). Biophysical aspects of neuro-muscular transmission. Prog. Biophys. Biophys. Chem.6, 121–170.
44
DiMauroS. (2011). A history of mitochondrial diseases. J. Inherit. Metab. Dis.34, 261–276. 10.1007/s10545-010-9082-x
45
DiMauroS.BonillaE.ZevianiM.NakagawaM.DeVivoD. C. (1985). Mitochondrial myopathies. Ann. Neurol.17, 521–538. 10.1002/ana.410170602
46
DranceS. M. (1975). Doyne Memorial Lecture, 1975. Correlation of optic nerve and visual field defects in simple glaucoma. Trans. Ophthalmol. Soc. U. K.95, 288–296.
47
DranceS. M. (1992). Bowman Lecture. Glaucoma–changing concepts. Eye (Lond)6(Pt 4), 337–345. 10.1038/eye.1992.69
48
D'SouzaG. G.RammohanR.ChengS. M.TorchilinV. P.WeissigV. (2003). DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. J. Control. Release92, 189–197. 10.1016/S0168-3659(03)00297-9
49
EngelW. K.CunninghamG. G. (1963). Rapid examination of muscle tissue. An improved trichrome method for fresh-frozen biopsy sections. Neurology13, 919–923. 10.1212/WNL.13.11.919
50
FilostoM.ScarpelliM.CotelliM. S.VielmiV.TodeschiniA.GregorelliV.et al. (2011). The role of mitochondria in neurodegenerative diseases. J. Neurol.258, 1763–1774. 10.1007/s00415-011-6104-z
51
FinstererJ. (2006). Central nervous system manifestations of mitochondrial disorders. Acta Neurol. Scand.114, 217–238. 10.1111/j.1600-0404.2006.00671.x
52
FlammerJ.OrgülS.CostaV. P.OrzalesiN.KrieglsteinG. K.SerraL. M.et al. (2002). The impact of ocular blood flow in glaucoma. Prog. Retin. Eye Res.21, 359–393. 10.1016/S1350-9462(02)00008-3
53
GeijssenH. C.GreveE. L. (1990). Focal ischaemic normal pressure glaucoma versus high pressure glaucoma. Doc. Ophthalmol.75, 291–301. 10.1007/BF00164843
54
GodfraindT. (2004). Historical perspective: from early steps on calcium research to the identification of calcium antagonist prototypes and of the signaling functions of Ca2+, in Calcium Channel Blockers. Milestones in Drug Therapy, eds ParnhamM. J.BruinvelsJ. (Basel: Birkhäuser), 1–9.
55
GoldbergI. (1994). Therapeutic possibilities for calcium channel blockers in glaucoma. Prog. Retin. Eye Res.13, 593–604. 10.1016/1350-9462(94)90023-X
56
GuevenN.NadikudiM.DanielA.ChhetriJ. (2016). Targeting mitochondrial function to treat optic neuropathy. Mitochondrion36, 7–14. 10.1016/j.mito.2016.07.013
57
GunterK. K.GunterT. E. (1994). Transport of calcium by mitochondria. J. Bioenerg. Biomembr.26, 471–485. 10.1007/BF00762732
58
HajnóczkyG.Robb-GaspersL. D.SeitzM. B.ThomasA. P. (1995). Decoding of cytosolic calcium oscillations in the mitochondria. Cell82, 415–424. 10.1016/0092-8674(95)90430-1
59
HalestrapA. P.RichardsonA. P. (2015). The mitochondrial permeability transition: a current perspective on its identity and role in ischaemia/reperfusion injury. J. Mol. Cell. Cardiol.78, 129–141. 10.1016/j.yjmcc.2014.08.018
60
HamP. B.III.RajuR. (2016). Mitochondrial function in hypoxic ischemic injury and influence of aging. Prog Neurobiol. 157, 92–116. 10.1016/j.pneurobio.2016.06.006
61
HarmanD. (1972). The biologic clock: the mitochondria?J. Am. Geriatr. Soc.20, 145–147. 10.1111/j.1532-5415.1972.tb00787.x
62
HeilbrunnL. V.WiercinskiF. J. (1947). The action of various cations on muscle protoplasm. J. Cell. Comp. Physiol.29, 15–32. 10.1002/jcp.1030290103
63
HodgkinA. L.KeynesR. D. (1957). Movements of labelled calcium in squid giant axons. J. Physiol.138, 253–281. 10.1113/jphysiol.1957.sp005850
64
HofmannF.BielM.FlockerziV. (1994). Molecular basis for Ca2+ channel diversity. Annu. Rev. Neurosci.17, 399–418. 10.1146/annurev.ne.17.030194.002151
65
HoppeU. C. (2010). Mitochondrial calcium channels. FEBS Lett.584, 1975–1981. 10.1016/j.febslet.2010.04.017
66
HoytW. F.FrisénL.NewmanN. M. (1973). Fundoscopy of nerve fiber layer defects in glaucoma. Invest. Ophthalmol.12, 814–829.
67
HuangW.FiletaJ.RaweI.QuJ.GrosskreutzC. L. (2010). Calpain activation in experimental glaucoma. Invest. Ophthalmol. Vis. Sci.51, 3049–3054. 10.1167/iovs.09-4364
68
HulkeJ. W. (1859). Iridectomy in glaucoma. Lancet74:515. 10.1016/S0140-6736(02)74363-8
69
HurstS.HoekJ.SheuS. S. (2017). Mitochondrial Ca2+ and regulation of the permeability transition pore. J. Bioenerg. Biomembr.49, 27–47. 10.1007/s10863-016-9672-x
70
ItoY.NakamuraS.TanakaH.TsurumaK.ShimazawaM.AraieM.et al. (2010). Lomerizine, a Ca2+ channel blocker, protects against neuronal degeneration within the visual center of the brain after retinal damage in mice. CNS Neurosci. Ther.16, 103–114. 10.1111/j.1755-5949.2009.00081.x
71
IzzottiA.BagnisA.SaccàS. C. (2006). The role of oxidative stress in glaucoma. Mutat. Res.612, 105–114. 10.1016/j.mrrev.2005.11.001
72
IzzottiA.SaccàS. C.LongobardiM.CartigliaC. (2010). Mitochondrial damage in the trabecular meshwork of patients with glaucoma. Arch. Ophthalmol.128, 724–730. 10.1001/archophthalmol.2010.87
73
JarrettS. G.LewinA. S.BoultonM. E. (2010). The importance of mitochondria in age-related and inherited eye disorders. Ophthalmic Res.44, 179–190. 10.1159/000316480
74
JeoungJ. W.SeongM. W.ParkS. S.KimD. M.KimS. H.ParkK. H. (2014). Mitochondrial DNA variant discovery in normal-tension glaucoma patients by next-generation sequencing. Invest. Ophthalmol. Vis. Sci.55, 986–992. 10.1167/iovs.13-12968
75
JohnsD. R. (1995). The ophthalmologic manifestations of mitochondrial disease. Semin. Ophthalmol.10, 295–302. 10.3109/08820539509063800
76
JonasJ. B.AungT.BourneR. R.BronA. M.RitchR.Panda-JonasS. (2017). Glaucoma. Lancet390, 2183–2193. 10.1016/S0140-6736(17)31469-1
77
JonasJ. B.BuddeW. M. (2000). Diagnosis and pathogenesis of glaucomatous optic neuropathy: morphological aspects. Prog. Retin. Eye Res.19, 1–40. 10.1016/S1350-9462(99)00002-6
78
JuW. K.KimK. Y.Duong-PolkK. X.LindseyJ. D.EllismanM. H.WeinrebR. N. (2010). Increased optic atrophy type 1 expression protects retinal ganglion cells in a mouse model of glaucoma. Mol. Vis.16, 1331–1342.
79
JuW. K.LiuQ.KimK. Y.CrowstonJ. G.LindseyJ. D.AgarwalN.et al. (2007). Elevated hydrostatic pressure triggers mitochondrial fission and decreases cellular ATP in differentiated RGC-5 cells. Invest. Ophthalmol. Vis. Sci.48, 2145–2151. 10.1167/iovs.06-0573
80
KajitaniN.KobuchiH.FujitaH.YanoH.FujiwaraT.YasudaT.et al. (2007). Mechanism of A23187-induced apoptosis in HL-60 cells: dependency on mitochondrial permeability transition but not on NADPH oxidase. Biosci. Biotechnol. Biochem.71, 2701–2711. 10.1271/bbb.70304
81
KamadaT.KinositaH. (1943). Disturbances initiated from naked surface of muscle protoplasm. Jpn. J. Zool.10, 469–493.
82
KamelK.FarrellM.O'BrienC. (2017). Mitochondrial dysfunction in ocular disease: focus on glaucoma. Mitochondrion35, 44–53. 10.1016/j.mito.2017.05.004
83
KarP.SamantaK.ShaikhS.ChowdhuryA.ChakrabortiT.ChakrabortiS. (2010). Mitochondrial calpain system: an overview. Arch. Biochem. Biophys.495, 1–7. 10.1016/j.abb.2009.12.020
84
KarakiH.OzakiH.HoriM.Mitsui-SaitoM.AmanoK.HaradaK.et al. (1997). Calcium movements, distribution, and functions in smooth muscle. Pharmacol. Rev.49, 157–230.
85
KeinanN.PahimaH.Ben-HailD.Shoshan-BarmatzV. (2013). The role of calcium in VDAC1 oligomerization and mitochondria-mediated apoptosis. Biochim. Biophys. Acta1833, 1745–1754. 10.1016/j.bbamcr.2013.03.017
86
KellyS. P.WalleyT. J. (1988). Effect of the calcium antagonist nifedipine on intraocular pressure in normal subjects. Br. J. Ophthalmol.72, 216–218. 10.1136/bjo.72.3.216
87
KirichokY.KrapivinskyG.ClaphamD. E. (2004). The mitochondrial calcium uniporter is a highly selective ion channel. Nature427, 360–364. 10.1038/nature02246
88
KitazawaY.ShiraiH.GoF. J. (1989). The effect of Ca2+ -antagonist on visual field in low-tension glaucoma. Graefes Arch. Clin. Exp. Ophthalmol.227, 408–412. 10.1007/BF02172889
89
KohlhardtM.BauerB.KrauseH.FleckensteinA. (1972a). Differentiation of the transmembrane Na and Ca channels in mammalian cardiac fibres by the use of specific inhibitors. Pflugers Arch.335, 309–322. 10.1007/BF00586221
90
KohlhardtM.BauerB.KrauseH.FleckensteinA. (1972b). New selective inhibitors of the transmembrane Ca conductivity in mammalian myocardial fibres. Studies with the voltage clamp technique. Experientia28, 288–289. 10.1007/BF01928693
91
KohlhardtM.BauerB.KrauseH.FleckensteinA. (1973). Selective inhibition of the transmembrane Ca conductivity of mammalian myocardial fibres by Ni, Co and Mn ions. Pflugers Arch.338, 115–123. 10.1007/BF00592747
92
KohlhardtM.FleckensteinA. (1980). Inhibition of the slow inward current by nifedipine in mammalian ventricular myocardium. Br. J. Clin. Pract.8(Suppl. 1), 3–8.
93
KolishettiN.DharS.ValenciaP. M.LinL. Q.KarnikR.LippardS. J.et al. (2010). Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc. Natl. Acad. Sci. U.S.A.107, 17939–17944. 10.1073/pnas.1011368107
94
KongG. Y.Van BergenN. J.TrounceI. A.CrowstonJ. G. (2009). Mitochondrial dysfunction and glaucoma. J. Glaucoma18, 93–100. 10.1097/IJG.0b013e318181284f
95
LandJ. M.ClarkJ. B. (1979). Mitochondrial myopathies. Biochem. Soc. Trans.7, 231–245. 10.1042/bst0070231
96
LascaratosG.ChauK. Y.ZhuH.GkotsiD.KingR.GoutI.et al. (2015). Resistance to the most common optic neuropathy is associated with systemic mitochondrial efficiency. Neurobiol. Dis.82, 78–85. 10.1016/j.nbd.2015.05.012
97
LascaratosG.Garway-HeathD. F.WilloughbyC. E.ChauK. Y.SchapiraA. H. (2012). Mitochondrial dysfunction in glaucoma: understanding genetic influences. Mitochondrion12, 202–212. 10.1016/j.mito.2011.11.004
98
LeeD.ShimM. S.KimK. Y.NohY. H.KimH.KimS. Y.et al. (2014). Coenzyme Q10 inhibits glutamate excitotoxicity and oxidative stress-mediated mitochondrial alteration in a mouse model of glaucoma. Invest. Ophthalmol. Vis. Sci.55, 993–1005. 10.1167/iovs.13-12564
99
LeeS.SheckL.CrowstonJ. G.Van BergenN. J.O'NeillE. C.O'HareF.et al. (2012). Impaired complex-I-linked respiration and ATP synthesis in primary open-angle glaucoma patient lymphoblasts. Invest. Ophthalmol. Vis. Sci.53, 2431–2437. 10.1167/iovs.12-9596
100
LeeS.Van BergenN. J.KongG. Y.ChrysostomouV.WaughH. S.O'NeillE. C.et al. (2011). Mitochondrial dysfunction in glaucoma and emerging bioenergetic therapies. Exp. Eye Res.93, 204–212. 10.1016/j.exer.2010.07.015
101
Levkovitch-VerbinH.QuigleyH. A.MartinK. R.ZackD. J.PeaseM. E.ValentaD. F. (2003). A model to study differences between primary and secondary degeneration of retinal ganglion cells in rats by partial optic nerve transection. Invest. Ophthalmol. Vis. Sci.44, 3388–3393. 10.1167/iovs.02-0646
102
LlinásR.SteinbergI. Z.WaltonK. (1976). Presynaptic calcium currents and their relation to synaptic transmission: voltage clamp study in squid giant synapse and theoretical model for the calcium gate. Proc. Natl. Acad. Sci. U.S.A.73, 2918–2922. 10.1073/pnas.73.8.2918
103
Lopez SanchezM. I.CrowstonJ. G.MackeyD. A.TrounceI. A. (2016). Emerging mitochondrial therapeutic targets in optic neuropathies. Pharmacol. Ther.165, 132–152. 10.1016/j.pharmthera.2016.06.004
104
LuftR. (1994). The development of mitochondrial medicine. Proc. Natl. Acad. Sci. U.S.A.91, 8731–8738. 10.1073/pnas.91.19.8731
105
LuftR.IkkosD.PalmieriG.ErnsterL.AfzeliusB. (1962). A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study. J. Clin. Invest.41, 1776–1804. 10.1172/JCI104637
106
LuongoT. S.LambertJ. P.GrossP.NwokediM.LombardiA. A.ShanmughapriyaS.et al. (2017). The mitochondrial Na+/Ca2+ exchanger is essential for Ca2+ homeostasis and viability. Nature545, 93–97. 10.1038/nature22082
107
MadeshM.HajnóczkyG. (2001). VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release. J. Cell. Bio.155, 1003–1016. 10.1083/jcb.200105057
108
MagnerM.KolárováH.HonzikT.ŠvandováI.ZemanJ. (2015). Clinical manifestation of mitochondrial diseases. Dev. Period Med.19, 441–449.
109
MannM.HaqW.ZabelT.GuentherE.ZrennerE.LadewigT. (2005). Age-dependent changes in the regulation mechanisms for intracellular calcium ions in ganglion cells of the mouse retina. Eur. J. Neurosci.22, 2735–2743. 10.1111/j.1460-9568.2005.04475.x
110
MarracheS.DharS. (2012). Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc. Natl. Acad. Sci. U.S.A.109, 16288–16293. 10.1073/pnas.1210096109
111
MilediR. (1973). Transmitter release induced by injection of calcium ions into nerve terminals. Proc. R. Soc. Lond. B. Biol. Sci.183, 421–425. 10.1098/rspb.1973.0026
112
MonicaM. L.HesseR. J.MesserliF. H. (1983). The effect of a calcium-channel blocking agent on intraocular pressure. Am. J. Ophthalmol.96:814. 10.1016/S0002-9394(14)71934-8
113
NeherE.SakabaT. (2008). Multiple roles of calcium ions in the regulation of neurotransmitter release. Neuron59, 861–872. 10.1016/j.neuron.2008.08.019
114
NetlandP. A.ChaturvediN.DreyerE. B. (1993). Calcium channel blockers in the management of low-tension and open-angle glaucoma. Am. J. Ophthalmol.115, 608–613. 10.1016/S0002-9394(14)71458-8
115
NetlandP. A.FekeG. T.KonnoS.GogerD. G.FujioN. (1996). Optic nerve head circulation after topical calcium channel blocker. J. Glaucoma5, 200–206. 10.1097/00061198-199606000-00010
116
NetlandP. A.GrosskreutzC. L.FekeG. T.HartL. J. (1995). Color Doppler ultrasound analysis of ocular circulation after topical calcium channel blocker. Am. J. Ophthalmol.119, 694–700. 10.1016/S0002-9394(14)72772-2
117
NewmanN. J.BiousseV. (2004). Hereditary optic neuropathies. Eye18, 1144–1160. 10.1038/sj.eye.6701591
118
NguyenD.AlaviM. V.KimK. Y.KangT.ScottR. T.NohY. H.et al. (2011). A new vicious cycle involving glutamate excitotoxicity, oxidative stress and mitochondrial dynamics. Cell Death Dis.2:e240. 10.1038/cddis.2011.117
119
NingJ.HuangB.WeiZ.LiW.ZhengH.MaL.et al. (2017). Mitochondria targeting and near-infrared fluorescence imaging of a novel heptamethine cyanine anticancer agent. Mol. Med. Rep.15, 3761–3766. 10.3892/mmr.2017.6451
120
OrthM.SchapiraA. H. (2001). Mitochondria and degenerative disorders. Am. J. Med. Genet.106, 27–36. 10.1002/ajmg.1425
121
OsborneN. N.ÁlvarezC. N.del Olmo AguadoS. (2014). Targeting mitochondrial dysfunction as in aging and glaucoma. Drug Discov. Today19, 1613–1622. 10.1016/j.drudis.2014.05.010
122
OsborneN. N.del Olmo-AguadoS. (2013). Maintenance of retinal ganglion cell mitochondrial functions as a neuroprotective strategy in glaucoma. Curr. Opin. Pharmacol.13, 16–22. 10.1016/j.coph.2012.09.002
123
OsborneN. N.LascaratosG.BronA. J.ChidlowG.WoodJ. P. (2006). A hypothesis to suggest that light is a risk factor in glaucoma and the mitochondrial optic neuropathies. Br. J. Ophthalmol.90, 237–241. 10.1136/bjo.2005.082230
124
OsborneN. N.LiG. Y.JiD.MortiboysH. J.JacksonS. (2008). Light affects mitochondria to cause apoptosis to cultured cells: possible relevance to ganglion cell death in certain optic neuropathies. J. Neurochem.105, 2013–2028. 10.1111/j.1471-4159.2008.05320.x
125
OsborneN. N.Núñez-ÁlvarezC.Del Olmo-AguadoS.Merrayo-LlovesJ. (2016a). Visual light effects on mitochondria: the potential implications in relation to glaucoma. Mitochondrion36, 29–35. 10.1016/j.mito.2016.11.009
126
OsborneN. N.Núñez-ÁlvarezC.JoglarB.Del Olmo-AguadoS. (2016b). Glaucoma: focus on mitochondria in relation to pathogenesis and neuroprotection. Eur. J. Pharmacol.787, 127–133. 10.1016/j.ejphar.2016.04.032
127
OsborneN. N.WoodJ. P.ChidlowG. (2005). Invited review: neuroprotective properties of certain beta-adrenoceptor antagonists used for the treatment of glaucoma. J. Ocul. Pharmacol. Ther.21, 175–181. 10.1089/jop.2005.21.175
128
OsborneN. N.WoodJ. P.ChidlowG.CassonR.DeSantisL.SchmidtK. G. (2004). Effectiveness of levobetaxolol and timolol at blunting retinal ischaemia is related to their calcium and sodium blocking activities: relevance to glaucoma. Brain Res. Bull.62, 525–528. 10.1016/S0361-9230(03)00070-4
129
OsborneN. N.WoodJ. P.CupidoA.MelenaJ.ChidlowG. (2002). Topical flunarizine reduces IOP and protects the retina against ischemia-excitotoxicity. Invest. Ophthalmol. Vis. Sci.43, 1456–1464.
130
ParkM. K.AshbyM. C.ErdemliG.PetersenO. H.TepikinA. V. (2001). Perinuclear, perigranular and sub-plasmalemmal mitochondria have distinct functions in the regulation of cellular calcium transport. EMBO J.20, 1863–1874. 10.1093/emboj/20.8.1863
131
PayneL. J.SlagleT. M.CheeksL. T.GreenK. (1990). Effect of calcium channel blockers on intraocular pressure. Ophthalmic Res.22, 337–341. 10.1159/000267044
132
PetersenO. H.BurdakovD.TepikinA. V. (1999). Polarity in intracellular calcium signaling. Bioessays21, 851–860. 10.1002/(SICI)1521-1878(199910)21:10<851::AID-BIES7>3.0.CO;2-F
133
Pinazo-DuránM. D.Zanón-MorenoV.Gallego-PinazoR.García-MedinaJ. J. (2015). Oxidative stress and mitochondrial failure in the pathogenesis of glaucoma neurodegeneration. Prog. Brain Res.220, 127–153. 10.1016/bs.pbr.2015.06.001
134
PozzanT.RizzutoR.VolpeP.MeldolesiJ. (1994). Molecular and cellular physiology of intracellular calcium stores. Physiol. Rev.74, 595–636.
135
PutneyJ. W.Jr.McKayR. R. (1999). Capacitative calcium entry channels. Bioessays21, 38–46. 10.1002/(SICI)1521-1878(199901)21:1<38::AID-BIES5>3.0.CO;2-S
136
QuigleyH. A.BromanA. T. (2006). The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol.90, 262–267. 10.1136/bjo.2005.081224
137
RasheedM. Z.TabassumH.ParvezS. (2017). Mitochondrial permeability transition pore: a promising target for the treatment of Parkinson's disease. Protoplasma254, 33–42. 10.1007/s00709-015-0930-2
138
ReuterH.StevensC. F.TsienR. W.YellenG. (1982). Properties of single calcium channels in cardiac cell culture. Nature297, 501–504. 10.1038/297501a0
139
RibasV. T.KochJ. C.MichelU.BährM.LingorP. (2017). Attenuation of axonal degeneration by calcium channel inhibitors improves retinal ganglion cell survival and regeneration after optic nerve crush. Mol. Neurobiol.54, 72–86. 10.1007/s12035-015-9676-2
140
RingerS. (1883). A further contribution regarding the influence of the different constituents of the blood on the contraction of the heart. J. Physiol.4, 29–42. 10.1113/jphysiol.1883.sp000120
141
RizzutoR.BernardiP.PozzanT. (2000). Mitochondria as all-round players of the calcium game. J. Physiol.529 (Pt 1), 37–47. 10.1111/j.1469-7793.2000.00037.x
142
RizzutoR.BriniM.MurgiaM.PozzanT. (1993). Microdomains with high Ca2+ close to IP3-sensitive channels that are sensed by neighboring mitochondria. Science262, 744–747. 10.1126/science.8235595
143
RizzutoR.De StefaniD.RaffaelloA.MammucariC. (2012). Mitochondria as sensors and regulators of calcium signalling. Nat. Rev. Mol. Cell Biol.13, 566–578. 10.1038/nrm3412
144
Robb-GaspersL. D.BurnettP.RutterG. A.DentonR. M.RizzutoR.ThomasA. P. (1998). Integrating cytosolic calcium signals into mitochondrial metabolic responses. EMBO J.17, 4987–5000. 10.1093/emboj/17.17.4987
145
RutterG. A.BurnettP.RizzutoR.BriniM.MurgiaM.PozzanT.et al. (1996). Subcellular imaging of intramitochondrial Ca2+ with recombinant targeted aequorin: significance for the regulation of pyruvate dehydrogenase activity. Proc. Natl. Acad. Sci. U.S.A.93, 5489–5494. 10.1073/pnas.93.11.5489
146
RutterG. A.FasolatoC.RizzutoR. (1998). Calcium and organelles: a two-sided story. Biochem. Biophys. Res. Commun.253, 549–557. 10.1006/bbrc.1998.9727
147
SadighianS.RostamizadehK.HosseiniM. J.HamidiM.Hosseini-MonfaredH. (2017). Magnetic nanogels as dual triggered anticancer drug delivery: toxicity evaluation on isolated rat liver mitochondria. Toxicol. Lett.278, 18–29. 10.1016/j.toxlet.2017.06.004
148
SakhraniN. M.PadhH. (2013). Organelle targeting: third level of drug targeting. Drug Des. Devel. Ther.7, 585–599. 10.2147/DDDT.S45614
149
SantaféJ.Martínez de IbarretaM. J.SegarraJ.MelenaJ. (1997). A long-lasting hypotensive effect of topical diltiazem on the intraocular pressure in conscious rabbits. Naunyn Schmiedebergs. Arch. Pharmacol.355, 645–650. 10.1007/PL00004996
150
SantaféJ.Martínez de IbarretaM. J.SegarraJ.MelenaJ. (1999). The effect of topical diltiazem on ocular hypertension induced by water loading in rabbits. Gen. Pharmacol.32, 201–205. 10.1016/S0306-3623(98)00196-7
151
SantaféJ.Martínez de IbarretaM. J.SegarraJ.MelenaJ.GarridoM. (1996). A complex interaction between topical verapamil and timolol on intraocular pressure in conscious rabbits. Naunyn Schmiedebergs. Arch. Pharmacol.354, 198–204. 10.1007/BF00178721
152
SavigniD. L.O'Hare DoigR. L.SzymanskiC. R.BartlettC. A.LozićI.SmithN. M.et al. (2013). Three Ca2+ channel inhibitors in combination limit chronic secondary degeneration following neurotrauma. Neuropharmacology75, 380–390. 10.1016/j.neuropharm.2013.07.034
153
ScarpaA.AzzoneG. F. (1970). The mechanism of ion translocation in mitochondria. 4. Coupling of K+ efflux with Ca2+ uptake. Eur. J. Biochem.12, 328–335. 10.1111/j.1432-1033.1970.tb00854.x
154
SchaeferA. M.McFarlandR.BlakelyE. L.HeL.WhittakerR. G.TaylorR. W.et al. (2008). Prevalence of mitochondrial DNA disease in adults. Ann. Neurol.63, 35–39. 10.1002/ana.21217
155
SchiekeS. M.PhillipsD.McCoyJ. P.Jr.AponteA. M.ShenR. F.BalabanR. S.et al. (2006). The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J. Biol. Chem.281, 27643–27652. 10.1074/jbc.M603536200
156
SchneiderM. F.ChandlerW. K. (1973). Voltage dependent charge movement of skeletal muscle: a possible step in excitation-contraction coupling. Nature242, 244–246. 10.1038/242244a0
157
SchrierS. A.FalkM. J. (2011). Mitochondrial disorders and the eye. Curr. Opin. Ophthalmol.22, 325–331. 10.1097/ICU.0b013e328349419d
158
SelminF.MagriG.GennariC. G.MarchianòS.FerriN.PellegrinoS. (2017). Development of poly(lactide-co-glycolide) nanoparticles functionalized with a mitochondria penetrating peptide. J. Pept. Sci.23, 182–188. 10.1002/psc.2952
159
SeltM.BartlettC. A.HarveyA. R.DunlopS. A.FitzgeraldM. (2010). Limited restoration of visual function after partial optic nerve injury; a time course study using the calcium channel blocker lomerizine. Brain Res. Bull.81, 467–471. 10.1016/j.brainresbull.2009.11.004
160
SeoA. Y.JosephA. M.DuttaD.HwangJ. C.ArisJ. P.LeeuwenburghC. (2010). New insights into the role of mitochondria in aging: mitochondrial dynamics and more. J. Cell Sci.123(Pt 15), 2533–2542. 10.1242/jcs.070490
161
ShapiraY.HarelS.RussellA. (1977). Mitochondrial encephalomyopathies: a group of neuromuscular disorders with defects in oxidative metabolism. Isr. J. Med. Sci.13, 161–164. 10.1159/000400702
162
SharmaA. K.RohrerB. (2004). Calcium-induced calpain mediates apoptosis via caspase-3 in a mouse photoreceptor cell line. J. Biol. Chem.279, 35564–35572. 10.1074/jbc.M401037200
163
Shoshan-BarmatzV.KrelinY.Shteinfer-KuzmineA.ArifT. (2017). Voltage-dependent anion channel 1 as an emerging drug target for novel anti-cancer therapeutics. Front. Oncol.7:154. 10.3389/fonc.2017.00154
164
ShyG. M.GonatasN. K. (1964). Human myopathy with giant abnormal mitochondria. Science145, 493–496. 10.1126/science.145.3631.493
165
SiegnerS. W.NetlandP. A.SchroederA.EricksonK. A. (2000). Effect of calcium channel blockers alone and in combination with antiglaucoma medications on intraocular pressure in the primate eye. J. Glaucoma9, 334–339. 10.1097/00061198-200008000-00009
166
SommerA. (1989). Intraocular pressure and glaucoma. Am. J. Ophthalmol.107, 186–188. 10.1016/0002-9394(89)90221-3
167
SorrentinoV.RizzutoR. (2001). Molecular genetics of Ca2+ stores and intracellular Ca2+ signalling. Trends Pharmacol. Sci.22, 459–464. 10.1016/S0165-6147(00)01760-0
168
SripetchwandeeJ.SanitJ.ChattipakornN.ChattipakornS. C. (2013). Mitochondrial calcium uniporter blocker effectively prevents brain mitochondrial dysfunction caused by iron overload. Life Sci.92, 298–304. 10.1016/j.lfs.2013.01.004
169
StilesP. G. (1901). On the rhythmic activity of the oesophagus and the influence upon it of various media. Am. J. Physiol.5, 338–357.
170
StoneE. M.FingertJ. H.AlwardW. L.NguyenT. D.PolanskyJ. R.SundenS. L.et al. (1997). Identification of a gene that causes primary open angle glaucoma. Science275, 668–670. 10.1126/science.275.5300.668
171
TakaiY.KishimotoA.IwasaY.KawaharaY.MoriT.NishizukaY. (1979). Calcium-dependent activation of a multifunctional protein kinase by membrane phospholipids. J. Biol. Chem.254, 3692–3695.
172
TakiharaY.InataniM.EtoK.InoueT.KreymermanA.MiyakeS.et al. (2015). In vivo imaging of axonal transport of mitochondria in the diseased and aged mammalian CNS. Proc. Natl. Acad. Sci. U.S.A.112, 10515–10520. 10.1073/pnas.1509879112
173
TanW.ColombiniM. (2007). VDAC closure increases calcium ion flux. Biochim. Biophys. Acta1768, 2510–2515. 10.1016/j.bbamem.2007.06.002
174
TanwarM.DadaT.SihotaR.DadaR. (2010). Mitochondrial DNA analysis in primary congenital glaucoma. Mol. Vis.16, 518–533.
175
TezelG. (2006). Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog. Retin. Eye Res.25, 490–513. 10.1016/j.preteyeres.2006.07.003
176
TezelG. (2009). The role of glia, mitochondria, and the immune system in glaucoma. Invest. Ophthalmol. Vis. Sci.50, 1001–1012. 10.1167/iovs.08-2717
177
ThamY. C.LiX.WongT. Y.QuigleyH. A.AungT.ChengC. Y. (2014). Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology121, 2081–2090. 10.1016/j.ophtha.2014.05.013
178
ToriuN.AkaikeA.YasuyoshiH.ZhangS.KashiiS.HondaY.et al. (2000). Lomerizine, a Ca2+ channel blocker, reduces glutamate-induced neurotoxicity and ischemia/reperfusion damage in rat retina. Exp. Eye Res.70, 475–484. 10.1006/exer.1999.0809
179
ToriuN.SasaokaM.ShimazawaM.SugiyamaT.HaraH. (2001). Effects of lomerizine, a novel Ca2+ channel blocker, on the normal and endothelin-1-disturbed circulation in the optic nerve head of rabbits. J. Ocul. Pharmacol. Ther.17, 131–149. 10.1089/10807680151125456
180
TsaiC. W.WuY.PaoP. C.PhillipsC. B.WilliamsC.MillerC.et al. (2017). Proteolytic control of the mitochondrial calcium uniporter complex. Proc. Natl. Acad. Sci. U.S.A.114, 4388–4393. 10.1073/pnas.1702938114
181
TsienR. W.BarrettC. F. (2000). A brief history of calcium channel discovery, in Madame Curie Bioscience Database [Internet]. (Austin, TX: Landes Bioscience).
182
Van BergenN. J.ChakrabartiR.O'NeillE. C.CrowstonJ. G.TrounceI. A. (2011). Mitochondrial disorders and the eye. Eye Brain3, 29–47. 10.1097/ICU.0b013e328349419d
183
Van BergenN. J.CrowstonJ. G.CraigJ. E.BurdonK. P.KearnsL. S.SharmaS.et al. (2015). Measurement of systemic mitochondrial function in advanced primary open-angle glaucoma and Leber hereditary optic neuropathy. PLoS ONE10:e0140919. 10.1371/journal.pone.0140919
184
VasingtonF. D.MurphyJ. V. (1962). Ca ion uptake by rat kidney mitochondria and its dependence on respiration and phosphorylation. J. Biol. Chem.237, 2670–2677.
185
VecinoE.RodriguezF. D.RuzafaN.PereiroX.SharmaS. C. (2016). Glia-neuron interactions in the mammalian retina. Prog. Retin. Eye Res.51, 1–40. 10.1016/j.preteyeres.2015.06.003
186
von GraefeA. (1857). Ueber kie Wirkung der Iridectomie bei Glaukom. Graefes Arch. Ophthalmol.3:456.
187
VoslerP. S.BrennanC. S.ChenJ. (2008). Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. Mol. Neurobiol.38, 78–100. 10.1007/s12035-008-8036-x
188
WallaceD. C. (1994). Mitochondrial DNA sequence variation in human evolution and disease. Proc. Natl. Acad. Sci. U.S.A.91, 8739–8746. 10.1073/pnas.91.19.8739
189
WatanabeM.FukudaY. (2002). Survival and axonal regeneration of retinal ganglion cells in adult cats. Prog. Retin. Eye Res.21, 529–553. 10.1016/S1350-9462(02)00037-X
190
WeinrebR. N.AungT.MedeirosF. A. (2014). The pathophysiology and treatment of glaucoma: a review. JAMA311, 1901–1911. 10.1001/jama.2014.3192
191
WiggsJ. L. (2007). Genetic etiologies of glaucoma. Arch. Ophthalmol.125, 30–37. 10.1001/archopht.125.1.30
192
WilliamsG. S.BoymanL.ChikandoA. C.KhairallahR. J.LedererW. J. (2013). Mitochondrial calcium uptake. Proc. Natl. Acad. Sci. U.S.A.110, 10479–10486. 10.1073/pnas.1300410110
193
WilliamsP. A.HarderJ. M.FoxworthN. E.CochranK. E.PhilipV. M.PorciattiV.et al. (2017). Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science355, 756–760. 10.1126/science.aal0092
194
WojdaU.SalinskaE.KuznickiJ. (2008). Calcium ions in neuronal degeneration. IUBMB Life60, 575–590. 10.1002/iub.91
195
WongL. J.ScagliaF.GrahamB. H.CraigenW. J. (2010). Current molecular diagnostic algorithm for mitochondrial disorders. Mol. Genet. Metab.100, 111–117. 10.1016/j.ymgme.2010.02.024
196
WongT. Y.MitchellP. (2007). The eye in hypertension. Lancet369, 425–435. 10.1016/S0140-6736(07)60198-6
197
YamadaY. (2014). Development of the MITO-porter, a nano device for mitochondrial drug delivery via membrane fusion. Yakugaku Zasshi134, 1143–1155. 10.1248/yakushi.14-00191
198
YamadaY.HarashimaH. (2017). MITO-Porter for mitochondrial delivery and mitochondrial functional analysis. Handb. Exp. Pharmacol.240, 475–472. 10.1007/164_2016_4
199
YamadaY.MunechikaR.KawamuraE.SakuraiY.SatoY.HarashimaH. (2017). Mitochondrial delivery of doxorubicin using MITO-Porter kills drug-resistant renal cancer cells via mitochondrial toxicity. J. Pharm. Sci.106, 2428–2437. 10.1016/j.xphs.2017.04.058
200
YamadaY.NakamuraK.AbeJ.HyodoM.HagaS.OzakiM.et al. (2015). Mitochondrial delivery of Coenzyme Q10 via systemic administration using a MITO-Porter prevents ischemia/reperfusion injury in the mouse liver. J. Control. Release213, 86–95. 10.1016/j.jconrel.2015.06.037
201
YamamotoK.SatoK.YukitaM.YasudaM.OmodakaK.RyuM.et al. (2017). The neuroprotective effect of latanoprost acts via klotho-mediated suppression of calpain activation after optic nerve transection. J. Neurochem.140, 495–508. 10.1111/jnc.13902
202
Yu-Wai-ManP.GriffithsP. G.ChinneryP. F. (2011). Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies. Prog. Retin. Eye Res.30, 81–114. 10.1016/j.preteyeres.2010.11.002
203
ZhangX. Y.ZhangP. Y. (2016). Mitochondria targeting nano agents in cancer therapeutics. Oncol. Lett.12, 4887–4890. 10.3892/ol.2016.5302
204
ZhangY.ZhangC.ChenJ.LiuL.HuM.LiJ.et al. (2017). Trackable mitochondria-targeting nanomicellar loaded with doxorubicin for overcoming drug resistance. ACS Appl. Mater. Interfaces9, 25152–25163. 10.1021/acsami.7b07219
205
ZhouF.XingD.WuB.WuS.OuZ.ChenW. R. (2010). New insights of transmembranal mechanism and subcellular localization of noncovalently modified single-walled carbon nanotubes. Nano Lett.10, 1677–1681. 10.1021/nl100004m
Summary
Keywords
calcium, mitochondria, glaucoma, mitochondrial drug delivery system, calcium channel blockers
Citation
Cheung LTY, Manthey AL, Lai JSM and Chiu K (2017) Targeted Delivery of Mitochondrial Calcium Channel Regulators: The Future of Glaucoma Treatment?. Front. Neurosci. 11:648. doi: 10.3389/fnins.2017.00648
Received
05 September 2017
Accepted
07 November 2017
Published
22 November 2017
Volume
11 - 2017
Edited by
Victor Tapias, Weill Cornell Medical College, United States
Reviewed by
Rolf Sprengel, Max Planck Institute for Medical Research (MPG), Germany; Selva Baltan, Cleveland Clinic Lerner College of Medicine, United States
Updates
Copyright
© 2017 Cheung, Manthey, Lai and Chiu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Kin Chiu datwai@hku.hk
This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.